ClinicalTrials.gg
RecruitingNCT07664735Updated Nov 12, 2026

A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

A Phase 1 interventional study of OPB-201 in Endometrial Cancer Recurrent, Endometrial Cancer and Advanced Endometrial Cancer, sponsored by Outpace Bio, Inc.. Recruiting at 5 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Outpace Bio, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 12, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 715 studies in Endometrial Neoplasms with a site in United States — 197 open to participants now, 286 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
414th of 591
30 · median 60
Started
2026
with 45 others
Phase 1
192 of 715
50 open now
Primary completion
2030-06
later than 260 of 285 live
Registered
698th of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 414th largest by planned enrollment of the 591 interventional ones that give a count, is one of 46 that started in 2026, is one of 192 in phase 1, reaches primary completion later than 260 of the 285 other live ones, and was the 698th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

197 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

191 more — sign in →

All 197 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if OPB-201 is safe in recurrent endometrial and platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-201. Participants will have their own T cells modified in a laboratory and given back to them as OPB-201 in this one-time treatment. Participants will be in the hospital when they receive OPB-201 and then be checked at the clinical site frequently for the first few months.

Read the detailed description

A phase 1a/b study to evaluate the safety and efficacy of OPB-201, an autologous PReferentially expressed Antigen of MElanoma (PRAME) T cell receptor (TCR) T cell therapy in recurrent endometrial and platinum-resistant ovarian cancer.

03

Conditions studied

  • Endometrial Cancer Recurrent
  • Endometrial Cancer
  • Advanced Endometrial Cancer
  • Ovarian Cancer
  • Ovarian Cancer Recurrent
  • Platinum Resistant Ovarian Cancer
  • Endometrial Cancers

Keywords

  • Outpace
  • Ovarian cancer
  • Endometrial cancer
  • advanced ovarian cancer
  • advanced endometrial cancer
  • cell therapy
  • TCR-T
  • TCR
  • PRAME directed TCR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years of age at the time of signing the form.
  2. confirmed diagnosis of endometrial cancer, epithelial ovarian, peritoneal, or fallopian tube cancer based on local histopathological findings.
  3. Received at least 1 including a platinum-based chemotherapy.
  4. Received prior therapy with a PARP inhibitor if the subject has a known germline or somatic BRCA1/2 mutation.
  5. .
  6. Consent to provide archived tumor tissue sample.
  7. performance status of 0 or 1.
  8. Adequate organ function.
  9. HLA-A *02:01 or HLA-A *02:02
  10. PRAME positive tumor

Exclusion criteria

Exclusion Criteria:

  1. Women of who are pregnant or breastfeeding.
  2. Uncontrolled bacterial, fungal, or viral infections.
  3. Active infection requiring systemic therapy.
  4. Bleeding or thrombotic disorders or at risk for severe hemorrhage.
  5. Any form of primary immunodeficiency.
  6. Had an allogenic tissue/solid organ transplant.
  7. Active disease.
  8. Concurrent treatment with systemic high dose .
  9. Unresolved acute effects of any prior therapy.
  10. Other exclusions as stated in the protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    OPB-201 Treatment Arm

    OPB-201 Treatment Arm

    Biological: OPB-201

Interventions

  • BiologicalOPB-201

    A multi-transgene autologous TCR T cell therapy with optimized alpha and beta chains of a TCR specific for a peptide derived from PRAME and a designed protein which enhances TCR T cell potency.

06

What researchers measure

Primary outcomes

  1. Incidence of all treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs); deaths due to TEAEs and all deaths.

    Incidence of all treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs); deaths due to TEAEs and all deaths.

    Time frame: 2 years

  2. Incidence of dose-limiting-toxicities (DLTs)

    Incidence of dose-limiting-toxicities (DLTs)

    Time frame: 28 days

  3. To determine the maximum tolerated dose (MTD) of OPB-201 and/or recommended Phase 1b dose(s)

    To determine the maximum tolerated dose (MTD) of OPB-201 and/or recommended Phase 1b dose(s)

    Time frame: 2 years

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2030, 48 months after the start.

Of 88 industry-sponsored phase 1 interventional studies under Endometrial Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 69. This study's planned 48 months is below that.

Counting every sponsor, half of 131 studies reached it within 61 months; a quarter within 46 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 24, 2026
StartActual
Jun 30, 2026
Primary completionEst.
Jun 2030
CompletionEst.
Sep 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
5 sites added — first site in United States
Show 5 added (5 United States)
  • UCSF - Helen Diller Family Comprehensive Cancer Center · San Francisco, United States
  • Emory - Winship Cancer Institute · Atlanta, United States
  • Karmanos Cancer Institute · Detroit, United States
  • University of Minnesota · Minneapolis, United States
  • MD Anderson Cancer Center · Houston, United States
Oct 26, 2026
Primary outcomes
3 edited
What changed in the outcomes
  • ChangedBefore SafetyNow Incidence of all treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs); deaths due to TEAEs and all deaths.Time frame: 2 years
  • ChangedBefore SafetyNow Incidence of dose-limiting-toxicities (DLTs)Time frame: 28 days
  • ChangedBefore SafetyNow To determine the maximum tolerated dose (MTD) of OPB-201 and/or recommended Phase 1b dose(s)Time frame: 2 years
Oct 26, 2026
Title
A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.→A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
across 2 updates, Oct 26, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Title A Phase 1 Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
    + 1 other change: verification date
  2. Oct 26, 2026
    Not yet recruiting→Recruiting
    5 sites added — first site in United States
    Show 5 added (5 United States)
    • UCSF - Helen Diller Family Comprehensive Cancer Center · San Francisco, United States
    • Emory - Winship Cancer Institute · Atlanta, United States
    • Karmanos Cancer Institute · Detroit, United States
    • University of Minnesota · Minneapolis, United States
    • MD Anderson Cancer Center · Houston, United States
    Primary outcomes 3 edited
    What changed in the outcomes
    • ChangedBefore SafetyNow Incidence of all treatment-emergent adverse events (TEAEs); Grade 3, 4, 5 TEAEs, serious adverse events (SAEs); deaths due to TEAEs and all deaths.Time frame: 2 years
    • ChangedBefore SafetyNow Incidence of dose-limiting-toxicities (DLTs)Time frame: 28 days
    • ChangedBefore SafetyNow To determine the maximum tolerated dose (MTD) of OPB-201 and/or recommended Phase 1b dose(s)Time frame: 2 years
    Title A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07664735
Lead sponsor
Outpace Bio, Inc.
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Jun 30, 2026
Primary completion
Jun 2030 (estimated)
Completion
Sep 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

John Ferraro
Contact
jferraro@outpacebio.vom
3039290208

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion